quinazolines has been researched along with gsk690693 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boddapati, S; Gray, JW; Iacovides, DC; Johnson, AB; Korkola, J; Wang, N | 1 |
| Bayani, N; Billig, J; Collisson, EA; Cooper, B; Esch, A; Feiler, H; Gray, JW; Griffith, OL; Heiser, M; Hung, JL; Itani, S; Jakkula, L; Korkola, JE; Kuo, WL; Lu, Y; Mills, GB; Mukherjee, S; Oates, C; Spellman, PT; Thompson, W; Tomlin, C; Wang, NJ; Ziyad, S | 1 |
2 other study(ies) available for quinazolines and gsk690693
| Article | Year |
|---|---|
Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.
Topics: Breast Neoplasms; Cell Line, Tumor; Electrophoresis, Capillary; Female; Humans; Immunoassay; Isoenzymes; Lapatinib; Metabolic Networks and Pathways; Microfluidic Analytical Techniques; Nanotechnology; Oxadiazoles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines | 2013 |
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diamines; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Mutation; Oxadiazoles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction | 2015 |